Major pharmaceutical companies are being challenged by the U.S. government over allegations of overcharging low-income patients for medications. This legal action could impact millions who rely on affordable drugs under government programs. The claims suggest these companies violated pricing agreements meant to protect vulnerable populations. The Trump administration is pushing for accountability, which may lead to significant financial penalties and stricter regulatory oversight for the involved drugmakers. The outcome could set a precedent for future pricing practices in the industry.
